Navigation Links
Mexico's First Spinal Implant Using VTi's Interfuse is a Success
Date:1/12/2017

MEXICO’S FIRST SPINAL IMPLANT USING VTI’S INTERFUSE® IS A SUCCESS

VTI, Vertebral Technologies, Inc., announces the successful outcome of the first lumbar fusion procedure in Mexico using the InterFuse® laterally expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical Technologies to bring less-invasive surgical solutions to surgeons and their patients throughout Mexico.

Neurosurgeon Dr. José Antonio Pedrero Gil at the Hospital AIR in Villahermosa, Tabasco region in northern Mexico performed the first InterFuse® procedure on a 38-year old female patient with Grade 2 spondylolisthesis. At three months, the patient is completely pain free and is walking normally.

The InterFuse® spinal implant finally allows surgeons like Dr. Pedrero to implant a large footprint device through a minimally-invasive posterior to tranforaminal with an angled approach of 0° - 35°. The modularity of the implant allows it to be anatomically customized to the patient’s disc space. Dr. Pedrero stated “the InterFuse® device appeals to me because it was easy to use and the large footprint ensures fusion and also eliminates the risk of retropulsion.”

Dr. Pedrero likes to use the InterFuse® device in younger, active patients with acute disc herniation as well as in patients suffering from spondylolisthesis. segmental instability and spinal stenosis. The partnership between Biomedical Technologies and VTI was formally announced at the September AMCICO Spine Congress in Mexico City, organized by AMCICO (Asociacion Mexicana de Cirujanos de Columna / Spine Surgeons Association of Mexico).

VTI Vice President of International Sales, Ben Wasscher stated “Surgeons in over twenty countries around the world have recognized the benefits that the InterFuse modular cage can bring to their patients. The large footprint is especially effective for patients with poorer bone quality in preventing subsidence. It is great that InterFuse is now also available in Mexico.”

ABOUT BIOMED TECH. INTL. (BioMedical).
Founded in 2004, BioMedical Tech. Intl., is a private held company who focuses on bringing high quality medical products and innovative technology to surgeons. Their Sales Operations Centers are located throughout Mexico, in Mexico City (headquarters), Guadalajara, Tijuana, Monterrey, Chihuahua, Merida, Villahermosa, Veracruz, Hermosillo and with a range of Sub-distributors all around the country. BioMedical’s mission is “To allow people to live more fully and healthier by seeking excellent quality in the products we manage, and to deliver unbeatable service at the appropriate time.” For more information for VTI products in Mexico, contact Pedro Montero for sales at: +52 (55) 52638370.

ABOUT VTI (Vertebral Technologies, Inc.)
VTI (Vertebral Technologies, Inc.) is a privately held company based in Minneapolis, MN, USA. VTI is dedicated to the design, development, manufacturing and marketing of medical devices to address painful conditions of the spine through less-invasive surgical approaches. VTI’s products utilize its unique modular-assembly technology to deliver solutions optimized for both surgeons and their patients. VTI sells its InterFuse modular interbody fusion devices worldwide to-date.

For more information visit, http://www.vti-spine.com or contact Brian Thron at marketing(at)vti-spine(dot)com or +1.952-979-1811

Read the full story at http://www.prweb.com/releases/2017/01/prweb13977072.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. First of it's kind Back Pain Relief Clinic grand opening designed to help millions.
2. Vtesse Announces Dosing of First Patient in Australia in Phase 2b/3 Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease
3. Arterys Receives FDA Clearance For The First Zero-Footprint Medical Imaging Analytics Cloud Software With Deep Learning For Cardiac MRI
4. ProMIS Neurosciences Declares PMN 310 its First Lead Product for Development in Alzheimer’s Disease
5. Base Pair Biotechnologies, Inc. and Nexmos, Inc. Create the First DNA Aptamers that Inhibit Vitamin C Oxidation
6. Biohaven Enrolls First Patient in Pivotal Trial of BHV-4157 in Patients With Hereditary Spinocerebellar Ataxia
7. First Immunotherapy Treatment Guidelines Published for Hematologic and Prostate Cancers
8. Ionis and AstraZeneca Advance First Generation 2.5 LICA Drug into Preclinical Development to Treat Cardiovascular Disease
9. Raindrop Vision Procedure Performed for the First Time in New England
10. OncoSec Announces First Quarter Financial Results for Fiscal Year 2017
11. KBioBox Launches First Genetic Data BioInformatics Portal Accessible to Scientists for Off Target and Gene Edit Design Analysis. (Complimentary Trial)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Basel, Switzerland (PRWEB) , ... May 23, 2017 ... ... for R&D, celebrates this month its 20th anniversary, marking the occasion with a ... is sponsoring the meeting’s Welcome Reception and further extends an invitation to all ...
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... ... publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology ... the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Bacterial biofilms, surface ... molecules, can cause diverse pathologies ranging from food poisoning and catheter infections to gum ... is in the tens of billions of dollars per year, there is currently a ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... Stratevi, a ... expanded to the East Coast. It has opened an office in downtown Boston at ... are finding it increasingly more important to generate evidence on the value they provide, ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):